Sonnet BioTherapeutics has achieved a significant milestone in its Phase 1 SB101 trial for SON-1010, a targeted immunotherapeutic drug, by establishing a maximum tolerated dose of 1200 ng/kg ...

announced today that the results of SON-1010 at the highest dose have been formally evaluated by the Safety Review Committee in the Phase 1 SB101 clinical trial of SON-1010 (IL12-F H AB ...

Gerdau S/A Ord-2.96% R$36.01B ...

President Joe Biden said Friday he is blocking a $14.3 billion acquisition of US Steel by Japan’s Nippon Steel, marking a significant use of executive authority in the closing days of his ...

“We are encouraged by this topline safety data generated to date in our Phase 1 study. Given the history of safety concerns with rhIL-12 in its first human trials over 25 years ago, it is exciting to ...

Sonnet is currently seeking partnership opportunities to help support later stage development of SON-1010.” For more information about the Phase 1 SB101 trial in adult patients with advanced ...

China is both the world's largest producer and consumer of steel. Because of the enormous size of the Chinese steel industry, any change in domestic production can have an outsized impact on the ...

2-Year U.S. Treasury Note Continuous Contract $102.742-0.063-0.06% 5-Year U.S. Treasury Note Continuous Contract $106.195-0.148-0.14% 10-Year U.S. Treasury Note Continuous Contract $108.625-0.188 ...